VOR SEC Filings: 8-K, 10-Q, S-3 & 424B – Vor Biopharma

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Vor Biopharma Inc. Announces Board of Directors Changes

Jul 7, 2026

8-K

Vor Biopharma Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 12, 2026

8-K

Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China

Jun 8, 2026

8-K

Vor Bio Announces $75 Million Private Placement with TCGX

Mar 27, 2026

8-K

Vor Biopharma Highlights Promising Pipeline for Telitacicept at J.P. Morgan Healthcare Conference

Jan 12, 2026

8-K

Vor Biopharma Inc. Announces Departure of Chief Development Officer Dr. Qing Zuraw

Jan 2, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

[No Baby Shelf]* October 2026 ATM | Offering amount: $150,000,000 | Bank: William Blair & Company, L.L.C., RBC Capital Markets, LLC

Oct 30, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 13,876,032

Feb 5, 2026

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 50,999,711 | Warrants amount: 50,999,711

Dec 1, 2025

424B5

REGISTERED OFFERING

Nov 12, 2025

424B5

PENDING FIXED PRICE OFFERING | Bank: J.P. Morgan, Jefferies, Citigroup, TD Cowen

Nov 10, 2025

424B5

August 2025 ATM| Amount sold to date: $5,300,695

Aug 27, 2025

Registrations

TYPE

HEADLINE

FILED AT

S-3ASR

September 2026 SHELF

Sep 4, 2026

S-3

SHARE RESALE REGISTRATION

Apr 27, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 30, 2026

S-3

SHARE RESALE REGISTRATION

Jan 29, 2026

S-3/A

SHARE RESALE REGISTRATION

Nov 10, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Sep 24, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 27, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 27, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Aug 8, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Jul 29, 2025

DEFR14A

Form DEFR14A - Revised definitive proxy soliciting materials

Apr 30, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 8, 2025

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 5, 2026

Sokolove Jeremy Brett (Reporting)

Nov 4, 2026

RA Capital Healthcare Fund LP (Reporting)

Oct 5, 2026

RA Capital Healthcare Fund LP (Reporting)

Aug 26, 2026

SCHEDULE 13G/A

Venrock Healthcare Capital Partners III, L.P. (Filed by)

Aug 14, 2026

SCHEDULE 13G/A

Frazier Life Sciences Public Fund, L.P. (Filed by)

Aug 14, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

May 7, 2026

CORRESP

Form CORRESP - Correspondence

May 4, 2026

LETTER

Form UPLOAD - SEC-generated letter

May 1, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 5, 2026

CORRESP

Form CORRESP - Correspondence

Feb 2, 2026

LETTER

Form UPLOAD - SEC-generated letter

Jan 30, 2026

Vor Biopharma Inc. VOR · SEC Filings